Protective Role of (-)-Epicatechin on Trimethylamine-N-Oxide (TMAO)-Induced Cardiac Hypertrophy via SP1/SIRT1/SUMO1 Signaling Pathway
Open Access
- 17 October 2024
- journal article
- research article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (12) , 1335-1347
Abstract
(-)-Epicatechin (EPI) is beneficial for cardiovascular health. Trimethylamine N-oxide (TMAO), a gut microbe-derived food metabolite, is strongly associated with the risk of cardiovascular diseases. However, the effects and underlying mechanisms of EPI on TMAO-induced cardiac hypertrophy remain unclear. This study aimed to determine whether EPI inhibits TMAO-induced cardiac hypertrophy. Plasma levels of TMAO in control participants and patients with cardiac hypertrophy were measured and analyzed. Male C57BL/6 mice were randomly divided into control group, TMAO group, EPI group and TMAO + EPI group. According to the groups assignments, mice received intraperitoneal (i.p.) injection of normal saline or i.p. injection of TMAO (150 mg/kg/day) for 14 days. The EPI group was given intragastric (i.g.) administration of EPI alone (1 mg/kg/day) for 21 days, and TMAO + EPI group received i.g. administration of EPI for 7 days before starting i.p. injection of TMAO, continuing until the end of the TMAO treatment. Histological analyses of the mice’s hearts was accessed by H&E and Masson staining. In vitro, H9c2 cells were induced to hypertrophy by TMAO (10 µM) for 24 h and were pre-treated with or without EPI (10 µM) for 1 h. Protein level of cardiac hypertrophy markers and Sp1/SIRT1/SUMO1 pathway were determined by western blot. The plasma level of TMAO was 2.66 ± 1.59 μmol/L in patients with cardiac hypertrophy and 0.62 ± 0.30 μmol/L in control participants. EPI attenuated TMAO-induced hypertrophy in H9c2 cells. In vivo, TMAO induced cardiac hypertrophy and impaired the cardiac function of mice. Pathological staining showed that TMAO induced cardiac hypertrophy and collagen deposition in mice. EPI treatment improved the cardiac function, inhibited the myocardial hypertrophy induced by TMAO. EPI significantly attenuated the TMAO-induced upregulation of ANP and BNP and the downregulation of SP1, SIRT1 and SUMO1 in vivo and in vitro. EPI may suppress TMAO-induced cardiac hypertrophy by activating the Sp1/SIRT1/SUMO1 signaling pathway.Keywords
Funding Information
- National Natural Science Foundation of China (82000297, 81870169)
- the Postdoctoral Research Fund of China (2018M631963)
- the Support Project for Outstanding Young Talents of the First Affiliated Hospital of Harbin Medical University (2024YQ15)
- the Doctor Funds of the First Affiliated Hospital of Harbin Medical University (2019B09)
This publication has 55 references indexed in Scilit:
- SIRT1 activation attenuates cardiac fibrosis by endothelial-to-mesenchymal transitionBiomedicine & Pharmacotherapy, 2019
- Analysis of Sumoylation2019
- Targeting anti‐aging protein sirtuin (Sirt) in the diagnosis of idiopathic pulmonary fibrosisJournal of Cellular Biochemistry, 2018
- Trimethylamine N‐oxide as a risk marker for ischemic stroke in patients with atrial fibrillationJournal of Biochemical and Molecular Toxicology, 2018
- Activation and overexpression of Sirt1 attenuates lung fibrosis via P300Biochemical and Biophysical Research Communications, 2017
- (-)-Epicatechin improves insulin sensitivity in high fat diet-fed miceArchives of Biochemistry and Biophysics, 2016
- Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis RiskCell, 2016
- Intersections Between Microbiome and Heart Failure: Revisiting the Gut HypothesisJournal of Cardiac Failure, 2015
- Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease RiskCurrent Cardiology Reports, 2015
- Intestinal Microbiota-Dependent Phosphatidylcholine Metabolites, Diastolic Dysfunction, and Adverse Clinical Outcomes in Chronic Systolic Heart FailureJournal of Cardiac Failure, 2015